FDA drug‑evaluation chief warns against over‑reliance on placebo effect in trials

FDA drug‑evaluation chief warns against over‑reliance on placebo effect in trials The passage provides commentary from a long‑time FDA official about placebo methodology, but offers no concrete allegations, financial flows, or misconduct involving high‑level officials. It is largely descriptive and lacks actionable leads. Key insights: Robert Temple, a four‑decade FDA drug‑evaluation veteran, critiques current placebo usage.; He suggests three‑arm trial designs to better isolate placebo effects.; Temple notes that automatic blood‑pressure cuffs can eliminate observed placebo effects.